688520 神州细胞
交易中 04-11 13:02:00
资讯
新帖
简况
神州细胞-U03月10日遭主力抛售562万元
市场透视 · 03-10
神州细胞-U03月10日遭主力抛售562万元
神州细胞:获得《药物临床试验批准通知书》
每日经济新闻 · 03-06
神州细胞:获得《药物临床试验批准通知书》
神州细胞(688520.SH)控股子公司产品SCTT11获得药物临床试验批准通知书
智通财经 · 03-06
神州细胞(688520.SH)控股子公司产品SCTT11获得药物临床试验批准通知书
神州细胞:近日,公司控股子公司神州细胞工程有限公司收到国家药监局核准签发的《药物临床试验批准通知书》,同意公司自主研发的
美港电讯 · 03-06
神州细胞:近日,公司控股子公司神州细胞工程有限公司收到国家药监局核准签发的《药物临床试验批准通知书》,同意公司自主研发的
神州细胞-U03月05日遭主力抛售2227万元
市场透视 · 03-05
神州细胞-U03月05日遭主力抛售2227万元
神州细胞-U03月03日获主力加仓134万元
市场透视 · 03-03
神州细胞-U03月03日获主力加仓134万元
神州细胞抗PD-1单抗联合疗法获批,百利天恒GNC-038 四抗注射液杀入自免领域,强生古塞奇尤单抗在华获批克罗恩病适应症
医药经济报 · 03-01
神州细胞抗PD-1单抗联合疗法获批,百利天恒GNC-038 四抗注射液杀入自免领域,强生古塞奇尤单抗在华获批克罗恩病适应症
神州细胞: 产品取得注册证
每日经济新闻 · 02-28
神州细胞: 产品取得注册证
神州细胞(688520.SH)子公司神州细胞工程取得药品注册证书
智通财经 · 02-28
神州细胞(688520.SH)子公司神州细胞工程取得药品注册证书
利润飙升8829%!神州细胞华丽逆袭
药智网 · 02-28
利润飙升8829%!神州细胞华丽逆袭
神州细胞-U02月27日主力净流入1064万元 散户资金抛售
市场透视 · 02-27
神州细胞-U02月27日主力净流入1064万元 散户资金抛售
神州细胞营业利润激增8829.33%,“单品打天下”套路屡试不爽?
Ofweek维科网 · 02-27
神州细胞营业利润激增8829.33%,“单品打天下”套路屡试不爽?
上市公司动态 | 同花顺2024年净利增三成,中国铝业董事长辞任,神州细胞2024年扭亏
和讯 · 02-24
上市公司动态 | 同花顺2024年净利增三成,中国铝业董事长辞任,神州细胞2024年扭亏
神州细胞-U02月24日主力净流入419万元 散户资金抛售
市场透视 · 02-24
神州细胞-U02月24日主力净流入419万元 散户资金抛售
神州细胞披露2024年业绩快报 首次实现年度扭亏为盈
中新经纬 · 02-24
神州细胞披露2024年业绩快报 首次实现年度扭亏为盈
神州细胞发布2024年度业绩快报,盈利1.12亿元
证券之星 · 02-24
神州细胞发布2024年度业绩快报,盈利1.12亿元
神州细胞(688520.SH)2024年度净利润1.12亿元,扭亏为盈
智通财经 · 02-24
神州细胞(688520.SH)2024年度净利润1.12亿元,扭亏为盈
神州细胞:2024年净利润1.12亿元 同比扭亏为盈
美港电讯 · 02-24
神州细胞:2024年净利润1.12亿元 同比扭亏为盈
神州细胞:2024年度净利润1.12亿元
格隆汇资讯 · 02-24
神州细胞:2024年度净利润1.12亿元
加载更多
公司概况
公司名称:
北京神州细胞生物技术集团股份公司
所属行业:
医药制造业
上市日期:
2020-06-22
主营业务:
北京神州细胞生物技术集团股份公司是致力于研发具备差异化竞争优势生物药的创新型生物制药研发公司,专注于恶性肿瘤、自身免疫性疾病、感染性疾病和遗传病等多个治疗和预防领域的生物药产品研发和产业化。公司的主要产品为重组蛋白药物、抗体药物等。公司在发现及研发创新药的领域拥有较强的能力,自主建立了从靶点蛋白筛选到候选药物的全套创新生物药发现上游技术平台体系。
发行价格:
25.64
{"stockData":{"symbol":"688520","market":"SH","secType":"STK","nameCN":"神州细胞","latestPrice":39.3,"timestamp":1744347720000,"preClose":38.61,"halted":0,"volume":2058248,"delay":0,"changeRate":0.0179,"floatShares":445000000,"shares":445000000,"eps":-0.0587,"marketStatus":"交易中","change":0.69,"latestTime":"04-11 13:02:00","open":38.4,"high":39.9,"low":38.06,"amount":80508900,"amplitude":0.0477,"askPrice":39.31,"askSize":4,"bidPrice":39.3,"bidSize":64,"shortable":0,"etf":0,"ttmEps":-0.0587,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1744354800000},"marketStatusCode":2,"adr":0,"adjPreClose":38.61,"symbolType":"stock_kcb","openAndCloseTimeList":[[1744335000000,1744342200000],[1744347600000,1744354800000]],"highLimit":42.47,"lowLimit":34.75,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":445335714,"isCdr":false,"pbRate":-40.13,"roa":"--","roe":"0.0%","epsLYR":-0.89,"committee":0.528302,"marketValue":17502000000,"turnoverRate":0.0046,"status":0,"floatMarketCap":17502000000},"requestUrl":"/m/hq/s/688520","defaultTab":"news","newsList":[{"id":"2518211235","title":"神州细胞-U03月10日遭主力抛售562万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518211235","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518211235?lang=zh_cn&edition=full","pubTime":"2025-03-10 15:22","pubTimestamp":1741591367,"startTime":"0","endTime":"0","summary":"03月10日, 神州细胞-U股价跌1.00%,报收40.56元,成交金额9275万元,换手率0.51%,振幅2.93%,量比0.63。神州细胞-U今日主力资金净流出562万元,连续5日净流出,上一交易日主力净流出152万元。该股近5个交易日下跌5.21%,主力资金累计净流出4774万元,其中1个交易日为股价上涨时净流出;近20日主力资金累计净流出4822万元,其中净流出天数为13日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310165425abf2905c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310165425abf2905c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688520"],"gpt_icon":0},{"id":"2517137745","title":"神州细胞:获得《药物临床试验批准通知书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2517137745","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517137745?lang=zh_cn&edition=full","pubTime":"2025-03-06 18:23","pubTimestamp":1741256589,"startTime":"0","endTime":"0","summary":"每经AI快讯,神州细胞3月6日晚间发布公告称,近日,北京神州细胞生物技术集团股份公司控股子公司神州细胞工程有限公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》,同意公司自主研发的产品SCTT11注射液开展甲状腺眼病适应症的临床试验。由于药物临床试验过程中不可预测因素较多,临床试验、审评和审批的结果以及时间都具有一定的不确定性,敬请广大投资者谨慎决策,注意防范投资风险。神州细胞的总经理、董事长均是谢良志,男,58岁,学历背景为博士。每经头条(nbdtoutiao)——专访全国政协委员、工信部原副部长王江平:AI进入实体经济的最大障碍是专业数据集不完善(记者 张喜威)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306182338963c096f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306182338963c096f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688520"],"gpt_icon":0},{"id":"2517213767","title":"神州细胞(688520.SH)控股子公司产品SCTT11获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2517213767","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517213767?lang=zh_cn&edition=full","pubTime":"2025-03-06 18:21","pubTimestamp":1741256482,"startTime":"0","endTime":"0","summary":"智通财经APP讯,神州细胞(688520.SH)发布公告,近日,公司控股子公司神州细胞工程有限公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》,同意公司自主研发的产品SCTT11注射液开展甲状腺眼病适应症的临床试验。目前,临床上对于甲状腺眼病患者仍存在较大的未满足医疗需求,亟待研发新的治疗药物。SCTT11产品为公司以差异化竞争优势为目标自主研发的用于治疗甲状腺眼病的单克隆抗体注射液。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1258655.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688520","BK0239","BK1141","BK1583","BK1576","03347"],"gpt_icon":0},{"id":"2517813731","title":"神州细胞:近日,公司控股子公司神州细胞工程有限公司收到国家药监局核准签发的《药物临床试验批准通知书》,同意公司自主研发的","url":"https://stock-news.laohu8.com/highlight/detail?id=2517813731","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517813731?lang=zh_cn&edition=full","pubTime":"2025-03-06 18:19","pubTimestamp":1741256342,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["03347","BK0239","BK1583","BK1141","BK1576","688520"],"gpt_icon":0},{"id":"2517196401","title":"神州细胞-U03月05日遭主力抛售2227万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517196401","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517196401?lang=zh_cn&edition=full","pubTime":"2025-03-05 15:20","pubTimestamp":1741159219,"startTime":"0","endTime":"0","summary":"03月05日, 神州细胞-U股价跌3.23%,报收40.80元,成交金额1.48亿元,换手率0.81%,振幅5.05%,量比0.83。神州细胞-U今日主力资金净流出2227万元,上一交易日主力净流出803万元。该股近5个交易日下跌0.10%,主力资金累计净流出1704万元;近20日主力资金累计净流出3730万元,其中净流出天数为13日。净流出前三个股分别为智飞生物、神州细胞-U、甘李药业。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305160235abe929b2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305160235abe929b2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688520","BK0239"],"gpt_icon":0},{"id":"2516500145","title":"神州细胞-U03月03日获主力加仓134万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516500145","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516500145?lang=zh_cn&edition=full","pubTime":"2025-03-03 15:22","pubTimestamp":1740986557,"startTime":"0","endTime":"0","summary":"03月03日, 神州细胞-U股价涨5.99%,报收42.79元,成交金额2.54亿元,换手率1.33%,振幅6.91%,量比1.53。神州细胞-U今日主力资金净流入134万元,连续3日净流入,上一交易日主力净流入126万元。近一年数据显示,该股主力连续3日净流入后,次日上涨概率为80.00%,平均涨幅为1.97%。该股近5个交易日上涨8.94%,主力资金累计净流入63万元,其中1个交易日为股价下跌时净流入;近20日主力资金累计净流出1629万元,其中净流出天数为13日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303164922a25cd21f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303164922a25cd21f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688520"],"gpt_icon":0},{"id":"2516580463","title":"神州细胞抗PD-1单抗联合疗法获批,百利天恒GNC-038 四抗注射液杀入自免领域,强生古塞奇尤单抗在华获批克罗恩病适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=2516580463","media":"医药经济报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516580463?lang=zh_cn&edition=full","pubTime":"2025-03-01 11:48","pubTimestamp":1740800927,"startTime":"0","endTime":"0","summary":"神州细胞抗PD-1单抗联合疗法获批,一线治疗肝癌2月28日,中国国家药监局官网公示,神州细胞控股子公司神州细胞工程递交的菲诺利单抗注射液与贝伐珠单抗注射液联合疗法的上市许可申请已获得批准。菲诺利单抗为神州细胞自主研发的重组人源化抗PD-1 IgG4型单克隆抗体注射液,首个适应症头颈部鳞状细胞癌已经于2025年2月获NMPA批准上市。这一消息标志着古塞奇尤单抗在克罗恩病适应症上的全球首个批准,为国内克罗恩病患者带来了新的希望。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250301115219abe18cd0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250301115219abe18cd0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4592","LU1061106388.HKD","BK4504","IE00B2B36J28.USD","LU1929549753.HKD","BK4559","JNJ","IE00B19Z3581.USD","LU1267930813.SGD","LU1674673691.USD","LU1032466523.USD","IE00BJT1NW94.SGD","LU1059921491.USD","IE0009355771.USD","LU1032955483.USD","IE00BVYPNW00.USD","LU2129689605.HKD","IE0034235303.USD","BK4550","LU1221951046.USD","IE00BDGV0183.EUR","LU0234570918.USD","LU2592432038.USD","LU1732799900.SGD","IE000M9KFDE8.USD","IE0002141913.USD","IE00B42XCP33.USD","LU0058720904.USD","LU1023059063.AUD","LU0795875169.SGD","LU0289739699.SGD","SG9999001440.SGD","LU1162221912.USD","LU2089984988.USD","SG9999002232.USD","LU2468319806.SGD","688506","LU1914381329.SGD","BK4023","LU2112291526.USD","LU2129689514.USD","LU1066051225.USD","BK4533","LU2505996509.AUD","LU2505996681.GBP","LU1244550221.USD","LU1732800096.USD","PD","IE00BGHQF631.EUR","BK4007","688520","LU2430703251.USD"],"gpt_icon":0},{"id":"2514334370","title":"神州细胞: 产品取得注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2514334370","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514334370?lang=zh_cn&edition=full","pubTime":"2025-02-28 17:28","pubTimestamp":1740734913,"startTime":"0","endTime":"0","summary":"2023年1至12月份,神州细胞的营业收入构成为:医药制造业占比100.0%。神州细胞的总经理、董事长均是谢良志,男,58岁,学历背景为博士。截至发稿,神州细胞市值为180亿元。道达号“个股趋势”提醒:1. 近30日内无机构对神州细胞-U进行调研。每经头条——10次承诺9次跳票!马斯克许诺的无人驾驶10年了也没兑现,特斯拉FSD在美德等国面临安全指控","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502281729139896271d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502281729139896271d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688520"],"gpt_icon":0},{"id":"2514343092","title":"神州细胞(688520.SH)子公司神州细胞工程取得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2514343092","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514343092?lang=zh_cn&edition=full","pubTime":"2025-02-28 17:28","pubTimestamp":1740734893,"startTime":"0","endTime":"0","summary":"智通财经APP讯,神州细胞(688520.SH)公告,公司控股子公司神州细胞工程有限公司(简称“神州细胞工程”)近日收到国家药品监督管理局核准签发的《药品注册证书》,菲诺利单抗注射液(商品名:安佑平®)和贝伐珠单抗注射液(商品名:安贝珠®)联合用于治疗既往未接受过系统治疗的不可切除或转移性肝细胞癌的注册申请获得批准。这是菲诺利单抗注射液第二个获批上市的适应症。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1256207.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688520","BK0239"],"gpt_icon":0},{"id":"2514367129","title":"利润飙升8829%!神州细胞华丽逆袭","url":"https://stock-news.laohu8.com/highlight/detail?id=2514367129","media":"药智网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514367129?lang=zh_cn&edition=full","pubTime":"2025-02-28 10:50","pubTimestamp":1740711000,"startTime":"0","endTime":"0","summary":"近日,神州细胞发布2024年业绩快报,成绩相当亮眼。2024年,神州细胞营业总收入25.13亿元,同比增长33.13%。营业利润达到5.68亿元,同比增长8829.33%,归属于母公司所有者的净利润为1.12亿元,成功扭亏为盈。目前,神州细胞上市产品包括1个重组蛋白药物、4个单抗药物,还有3个疫苗产品被纳入紧急使用。值得注意的是,神州细胞除了收入增加,利润增长更为惊喜。不过,神州细胞在疫苗领域的积累可能将在HPV疫苗上得到回报。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228105137a2572da3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228105137a2572da3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688520","BK0239"],"gpt_icon":0},{"id":"2514777824","title":"神州细胞-U02月27日主力净流入1064万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2514777824","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514777824?lang=zh_cn&edition=full","pubTime":"2025-02-27 15:21","pubTimestamp":1740640870,"startTime":"0","endTime":"0","summary":"02月27日, 神州细胞-U股价涨1.49%,报收41.45元,成交金额1.43亿元,换手率0.79%,振幅2.67%,量比1.02。神州细胞-U今日主力资金净流入1064万元,上一交易日主力净流出455万元。该股近5个交易日上涨7.49%,主力资金累计净流出223万元;近20日主力资金累计净流出2172万元,其中净流出天数为14日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227162759a2560593&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227162759a2560593&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688520","BK0239"],"gpt_icon":0},{"id":"2514511842","title":"神州细胞营业利润激增8829.33%,“单品打天下”套路屡试不爽?","url":"https://stock-news.laohu8.com/highlight/detail?id=2514511842","media":"Ofweek维科网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514511842?lang=zh_cn&edition=full","pubTime":"2025-02-27 14:02","pubTimestamp":1740636124,"startTime":"0","endTime":"0","summary":"2月25日,神州细胞发布2024年度业绩快报。据悉,2024年,神州细胞的研发费用预计同比减少21.14%-24.43%。据悉,到2024年三季度末,神州细胞的负债总额为32.89亿元,资产负债率依然维持在104.24%的高位。根据财报,2024年上半年,神州细胞支付其他与经营活动有关的现金5.12亿元,其中捐赠支出2.7亿元,占比52.73%。原文标题 : 神州细胞营业利润激增8829.33%,“单品打天下”套路屡试不爽?","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022714024596321a4c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022714024596321a4c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688520"],"gpt_icon":0},{"id":"2513287778","title":"上市公司动态 | 同花顺2024年净利增三成,中国铝业董事长辞任,神州细胞2024年扭亏","url":"https://stock-news.laohu8.com/highlight/detail?id=2513287778","media":"和讯","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513287778?lang=zh_cn&edition=full","pubTime":"2025-02-24 23:12","pubTimestamp":1740409920,"startTime":"0","endTime":"0","summary":"根据披露,公司首次受理日期为2023年03月02日,拟融资金额5.22亿元,保荐人为国金证券股份有限公司。近日,公司已向中国证监会报送了本次发行的备案申请材料并获接收。本次交易预计不构成重大资产重组,但构成关联交易。神州细胞2024年扭亏神州细胞公告称,营业总收入达到25.13亿元,同比增长33.13%;归属于母公司所有者的净利润为1.12亿元,实现扭亏为盈。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2025-02-24/doc-inemrenx1886840.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0187","02600","BK0196","BK1513","BK0095","BK0272","ACH","BK0010","BK0239","SG9999001069.SGD","BK0012","BK1568","BK1592","SG9999001051.SGD","SG9999002950.SGD","601600","SG9999001093.SGD","300033","BK0233","BK0188","BK0006","BK0028","688520","BK1175","BK0183","BK4153"],"gpt_icon":0},{"id":"2513728958","title":"神州细胞-U02月24日主力净流入419万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2513728958","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513728958?lang=zh_cn&edition=full","pubTime":"2025-02-24 18:57","pubTimestamp":1740394634,"startTime":"0","endTime":"0","summary":"02月24日, 神州细胞-U股价涨0.15%,报收39.28元,成交金额1.07亿元,换手率0.62%,振幅2.52%,量比1.10。神州细胞-U今日主力资金净流入419万元,上一交易日主力净流出445万元。该股近5个交易日上涨1.89%,主力资金累计净流出376万元;近20日主力资金累计净流出1736万元,其中净流出天数为13日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224200318abdae5c7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224200318abdae5c7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688520","BK0239"],"gpt_icon":0},{"id":"2513972726","title":"神州细胞披露2024年业绩快报 首次实现年度扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2513972726","media":"中新经纬","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513972726?lang=zh_cn&edition=full","pubTime":"2025-02-24 18:21","pubTimestamp":1740392480,"startTime":"0","endTime":"0","summary":"中新经纬注意到,神州细胞披露的2024半年报中显示,公司已实现半年度盈利。中新经纬注意到,本次业绩快报中的盈利,是神州细胞有披露年度业绩数据以来,即2016年以来首次实现年度净利润、归属于母公司所有者的净利润、归属于母公司所有者的扣除非经常性损益的净利润三项指标的首次转正,实现盈利。对此,神州细胞在2024年业绩快报中称,主要原因是公司核心产品安佳因销售稳定,其他上市产品销售收入增加。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224205343962e8068&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224205343962e8068&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688520"],"gpt_icon":0},{"id":"2513710104","title":"神州细胞发布2024年度业绩快报,盈利1.12亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513710104","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513710104?lang=zh_cn&edition=full","pubTime":"2025-02-24 17:07","pubTimestamp":1740388053,"startTime":"0","endTime":"0","summary":"证券之星消息,神州细胞近日即将发布2024年年报,根据2月24日发布的业绩快报,归属净利润盈利1.12亿元,同比增长128.27%。神州细胞(688520)主营业务:专注于恶性肿瘤、自身免疫性疾病、感染性疾病和遗传病等多个治疗和预防领域的生物药产品研发和产业化。该股最近90天内共有1家机构给出评级,买入评级1家。以上内容为证券之星据公开信息整理,由智能算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025022400022119.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688520","BK0239"],"gpt_icon":0},{"id":"2513712919","title":"神州细胞(688520.SH)2024年度净利润1.12亿元,扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2513712919","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513712919?lang=zh_cn&edition=full","pubTime":"2025-02-24 16:28","pubTimestamp":1740385714,"startTime":"0","endTime":"0","summary":"智通财经APP讯,神州细胞(688520.SH)披露2024年度业绩快报,公司实现营业总收入25.13亿元,同比增长33.13%;实现归属于母公司所有者的净利润1.12亿元,归属于母公司所有者的扣除非经常性损益的净利润4.74亿元,较上年同期相比均实现扭亏为盈。基本每股收益0.25元。报告期内,公司核心产品安佳因®销售稳定,其他上市产品的销售收入增加,公司整体营业收入较上年同期上升。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1253391.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688520"],"gpt_icon":0},{"id":"2513129397","title":"神州细胞:2024年净利润1.12亿元 同比扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2513129397","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513129397?lang=zh_cn&edition=full","pubTime":"2025-02-24 16:28","pubTimestamp":1740385685,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0239","688520"],"gpt_icon":0},{"id":"2513867712","title":"神州细胞:2024年度净利润1.12亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513867712","media":"格隆汇资讯","labels":["viewpoints"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513867712?lang=zh_cn&edition=full","pubTime":"2025-02-24 16:27","pubTimestamp":1740385663,"startTime":"0","endTime":"0","summary":"格隆汇2月24日丨神州细胞公布2024年度业绩快报,报告期内,公司实现营业总收入25.13亿元,同比增长33.13%;实现归属于母公司所有者的净利润1.12亿元,归属于母公司所有者的扣除非经常性损益的净利润4.74亿元,较上年同期相比均实现扭亏为盈。为加大已上市产品的市场推广力度,以及为即将商业化的产品扩充销售队伍,报告期内公司的销售费用有所增加。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224162752989090ca&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224162752989090ca&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"神州细胞:2024年度净利润1.12亿元","news_tag":"viewpoints","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688520"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1744347724251,"stockEarnings":[{"period":"1week","weight":-0.0723},{"period":"1month","weight":-0.0396},{"period":"3month","weight":0.1437},{"period":"6month","weight":0.0161},{"period":"1year","weight":-0.0069},{"period":"ytd","weight":0.0657}],"compareEarnings":[{"period":"1week","weight":-0.0354},{"period":"1month","weight":-0.0462},{"period":"3month","weight":0.0174},{"period":"6month","weight":0.0018},{"period":"1year","weight":0.0648},{"period":"ytd","weight":-0.0382}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"北京神州细胞生物技术集团股份公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"10296人(较上一季度增加3.33%)","perCapita":"43253股","listingDate":"2020-06-22","address":"北京市大兴区北京经济技术开发区科创七街31号院5号楼307","registeredCapital":"44533万元","survey":" 北京神州细胞生物技术集团股份公司是致力于研发具备差异化竞争优势生物药的创新型生物制药研发公司,专注于恶性肿瘤、自身免疫性疾病、感染性疾病和遗传病等多个治疗和预防领域的生物药产品研发和产业化。公司的主要产品为重组蛋白药物、抗体药物等。公司在发现及研发创新药的领域拥有较强的能力,自主建立了从靶点蛋白筛选到候选药物的全套创新生物药发现上游技术平台体系。","listedPrice":25.64},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.32.3","shortVersion":"4.32.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"神州细胞(688520)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供神州细胞(688520)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"神州细胞,688520,神州细胞股票,神州细胞股票老虎,神州细胞股票老虎国际,神州细胞行情,神州细胞股票行情,神州细胞股价,神州细胞股市,神州细胞股票价格,神州细胞股票交易,神州细胞股票购买,神州细胞股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"神州细胞(688520)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供神州细胞(688520)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}